GSK stock price forecast: GBX1,860.98 support holds as GSK trades flat

Traders Union
All News
Financial News
GSK falls 0.44% to GBX1,941.50 today

Highlights

GSK reports accelerating earnings and cash flow, underpinned by strong performance in vaccines and specialty medicines portfolios.
A diverse late-stage pipeline positions GSK for future product launches and sustained growth potential across multiple therapeutic areas.
Technical momentum remains bearish with GSK trading in a GBX1,897.45–1,985.55 range, as indicators signal a 68% probability of further downside.

Operational momentum builds amid sustained selling pressure

GSK has recorded accelerating earnings, cash flow, and pipeline activity, pointing to strengthened underlying operations. The company has also maintained its leadership in vaccines, specialty medications, HIV, and respiratory treatments, supporting stable revenue from a diverse range of therapeutic areas. Its robust late-stage pipeline provides additional options for future product launches and potential growth, though price action has remained under broader selling pressure.

Downside momentum as price loses short-term technical support

On the technical charts, GSK is trading below its MA-20 at GBX1,959.77 and its MA-50 at GBX1,954.97 on the H1 timeframe, while staying above the MA-200 at GBX1,860.98 on the daily chart. Immediate resistance is seen at the Ichimoku Kijun level of GBX1,966.00. Momentum indicators on the H1 chart are predominantly negative, with both MACD and Awesome Oscillator signaling continued selling pressure, while ADX remains neutral. RSI and Stoch RSI both flag seller dominance, and both CCI and BBP are reflecting oversold, seller-driven conditions.

Bearish bias prevails while consolidation dominates near-term outlook

In the near term, GSK is expected to oscillate within the range of GBX1,897.45 to GBX1,985.55, representing a typical volatility band relative to current levels. The probability of a move higher is estimated at 32%, while a further decline has a 68% likelihood. The baseline scenario anticipates price consolidation within this range; a break above immediate resistance would be needed for a bullish outcome, while loss of support below the lower end of the band could trigger additional downside.

Viktoras Karapetjanc, Traders Union analyst, notes GSK’s accelerating earnings and resilient business fundamentals. He sees broad sector strength, with diversification in core treatments and a strong late-stage pipeline providing future growth visibility. Despite wider selling pressure, he believes the company’s stable fundamentals could serve as a buffer. Karapetjanc maintains a constructive outlook while watching technical levels for a catalyst. "As long as GSK remains above its longer-term trend support, I expect its strong fundamentals to underpin price stability and offer a platform for recovery if sentiment shifts."

Previously it was reported that GSK shares were consolidating amid a broadly cautious technical outlook, following major strategic transactions and ongoing buybacks. Fresh signals of seller dominance and oversold conditions reinforce the near-term downside risk, making a breakdown below current support a scenario to watch closely.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.